Pancragen vs Retatrutide
A side-by-side research comparison of Pancragen and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pancragen | Retatrutide |
|---|---|---|
| Full name | Pancragen (Lys-Glu-Asp-Trp Pancreas Bioregulator) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound (peptide bioregulator) | Phase 3 Clinical Trial |
| Mechanism | As a signal peptide (Lys-Glu-Asp-Trp), it is proposed to regulate gene expression in pancreatic tissue, supporting normal endocrine and exocrine pancreatic function and carbohydrate metabolism. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | ~575 Da | 5,200 Da (approximate) |
| Half-life | Short (peptide) | 6 days |
| Bioavailability | Oral (encapsulated) or subcutaneous | High (SubQ) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 1-2 mg → titrate up to 12 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral capsule or subcutaneous | Subcutaneous injection |
Pancragen reported benefits
- Pancreatic tissue support
- Carbohydrate metabolism support (proposed)
- Metabolic resilience
- Short course-based protocol
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.